Navigation Links
Cord Blood America, Inc. Announces 2009 First Quarter Results
Date:5/21/2009

Company Reports Improved Operating Results, Strengthened Balance Sheet

To Host Conference Call for the Investment Community at 11 a.m. Eastern Time Today

SANTA MONICA, Calif., May 21 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today financial highlights for its 2009 first quarter for the period ended March 31, 2009. Some of the highlights include:

  • Improved operating results. The Company reduced its loss from operations from $0.4 million in its 2008 first quarter to $0.3 million in the 2009 first quarter.
  • Increased gross margin. The Company increased gross margin from 45.0% in the 2008 first quarter to 52.5% in the 2009 first quarter due to a more favorable mix of business, including a significantly higher percentage of revenue coming from the sale of umbilical cord blood stem cell preservation services.
  • Strengthened balance sheet. Indebtedness under the Company's convertible debentures declined from $6.8 million one year ago to $5.6 million at the end of the 2009 first quarter. Current liabilities fell from $13.6 million to $12.4 million.
  • Strong growth in billings for Company's core business. Cord's billings in the three-month period ended March 31, 2009 was $1.2 million, compared to $1.0 million in the year earlier period as reflected in the Company's deferred revenue. Deferred revenue consists of payments for enrollment in the program and processing of umbilical cord blood by customers whose samples have not yet been collected, as well as the pro-rata share of annual storage fees for customers whose samples were stored during the year.

"During the first quarter, we took significant initiatives to position the Company for growth," said Matthew Schissler, Founder and CEO. "We shifted our business focus to capitalize on the opportunities in the processing of umbilical cord blood, deemphasizing the advertising business, as reflected by our improved gross margin. We believe that the new administration will further support growth in the stem cell industry, and in our business of collecting and storing umbilical cord blood lifting the current ban on Federal funding for research on embryonic stem cell lines. The funding should accelerate the use of stem cells in treating diabetes, heart disease, and other major diseases, driving consumers to make the investments in storage and collection."

"We also strengthened our balance sheet, reducing indebtedness, extending maturities and regaining compliance with all of our key lenders," continued Schissler. "We believe with our improved financial condition that Cord Blood America is now well-positioned to consolidate the industry as well as to acquire or build its own state-of-the-art laboratory for the storage of multiple stem cell products including umbilical cord blood stem cells, which should further improve gross margin and profitability. We believe that the Company is well positioned to play a key role as stem cell therapies become a viable treatment modality."

Conference Call:

The Company will hold a conference call at 11 a.m. eastern time today to discuss the results and outlook for the balance of the year. Interested parties may access the call by dialing 877-627-6555 (domestically) or 719-325-4931 (internationally) and referencing passcode 3112433. There will also be a replay of the call available for five days at the conclusion of the call. Parties desiring to listen to the replay may dial 888-203-1112 (domestically) or 719-457-0820 (internationally) and use passcode 3112433

The conference call will also be webcast and will be available at http://www.investorcalendar.com/IC/CEPage.asp?ID=145176

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

              CONTACT:
              Paul Knopick
              E & E Communications
              949/707-5365
              pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Research points to a new way to protect kidneys threatened by insufficient blood or toxins
2. Cord Blood America CEO Matthew Schissler Expands on Thought Process in Owning Stem Cell Laboratory
3. Two Studies at AACE 2009 Annual Meeting Highlight Effects of Welchol(R) (colesevelam HCl) on Blood Glucose and LDL-C in Patients with Type 2 Diabetes
4. Viral Infection Might Trigger High Blood Pressure
5. Cord Blood America Receives Commitment for $2.3 Million to Fund Its Own Stem Cell Laboratory
6. New research confirms milestone study on blood pressure meds
7. AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
8. Study finds iron levels not predictive of survival for form of blood cancer
9. Genes Yield Clues to High Blood Pressure
10. Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study
11. Too-Low Blood Pressure Can Also Bring Danger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join ... This festival offers entertainment for everyone — from the avid gardener to the landscape ... very high quality event held in a grand venue, and we are certainly looking ...
(Date:4/21/2017)... ... April 21, 2017 , ... A new medical study ... replacement patients; post-operative recovery just might be even better than they imagined. Researchers ... osteoarthritis following surgery: 262 patients under 65 and 103 patients over 75. The ...
(Date:4/21/2017)... ... April 21, 2017 , ... National pest management association survey conducted in 2010 ... bug infestations over the 5-year period. In 2015 10% or US$750 million per annum ... bug infested properties. , The health and economic consequences of bed bug ...
(Date:4/21/2017)... ... April 21, 2017 , ... In a recently released ... a summer camp for kids in Dana Point, parents are challenged to find ways ... writers caution parents to find age appropriate activities that both reinforce their child’s learning ...
(Date:4/20/2017)... Carolina (PRWEB) , ... April 20, 2017 , ... ... of the fourth book in its growing library. The Greener The Grass, ... Quarterback and alumnus of Walnut Grove High School, shares a deeply personal, hard-earned ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... NEW YORK , April 19, 2017 The ... anticipated to showcase a healthy CAGR during the forecast period ... product type in the global digital mobile X-Ray devices market, ... 2,000 Mn in 2017, expanding at a CAGR of 7% ... create absolute $ opportunity of more than US$ 100 Mn ...
(Date:4/19/2017)... , April 19, 2017 Global Prostate ... report on the prostate cancer therapeutics market analyzes ... market. Increasing prevalence of prostate cancer, launch of ... the development of new drugs & therapeutic biological ... drug due to lesser side effects are some ...
(Date:4/19/2017)... 19, 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... company developing new treatments for cancer and other ... its previously announced underwritten public offering of 23,625,084 ... offering price of $2.00 per share, before deducting ... payable by Sorrento.  The net proceeds to Sorrento ...
Breaking Medicine Technology: